Pre-made Eluvixtamab benchmark antibody ( Bispecific scFv, anti-CD33;CD3E therapeutic antibody, Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Eluvixtamab (formerly AMG 330) is a bispecific antibody targeting cell surface markers CD33 and CD3, being developed by Amgen, for the treatment of acute.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-173-1mg	1mg	Inquiry
GMP-Bios-ab-173-10mg	10mg	Inquiry
GMP-Bios-ab-173-100mg	100mg	Inquiry
GMP-Bios-ab-173-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Eluvixtamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody
INN Name	Eluvixtamab
Target	CD33;CD3E
Format	Bispecific scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	na;na
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2020
Year Recommended	2021
Companies	Amgen
Conditions Approved	na
Conditions Active	Acute myeloid leukaemia
Conditions Discontinued	na
Development Tech	BiTE Technology